Retatrutide research peptide
Product at a glance
| Detail |
Information |
| Research name |
Retatrutide |
| Development code |
LY3437943 |
| Structure |
39-amino-acid peptide with a fatty-acid side chain |
| Research focus |
GLP-1R, GIPR and glucagon receptor signalling |
| Supplied form |
Lyophilised powder in a sealed vial |
| Listed vial options |
5, 10, 15, 20, 30, 40, 50 and 60 mg |
| Current availability |
See the size selector |
Listed sizes are labelled material amounts, not application instructions. Availability varies by option. This page describes the vial product, not a different product format.
Batch documents: check the exact match
Use the COA and verification page to check the compound name, batch identifier, sample description, methods and results. A certificate documents its tested sample; it is not automatically evidence for every size or batch of the same compound.
The current page identifies certificates for 10, 20, 30, 40 and 60 mg batches. It says other options may display a certificate from another size. Treat such a document as reference material unless its relationship to the actual supplied batch is documented. Ask for clarification if your option has no matching certificate.
HPLC purity alone does not establish total peptide content, sterility or endotoxin status. Do not assume a test was performed unless it is recorded.
What receptor research examines
Retatrutide is described in the literature as a triple-receptor agonist. In a laboratory context, that means researchers examine interactions with GLP-1, GIP and glucagon receptors, using defined experimental systems and measured signalling readouts.
Receptor expression, assay design and the material tested all affect interpretation. A result from a published study is not a performance guarantee for a research vial. This page makes no clinical or personal-use claims.
Read the Learning Hub for guidance on interpreting evidence, or watch the Retatrutide research explainer.
Laboratory storage and records
Follow the batch documentation and your laboratory’s approved procedures. Keep containers sealed and protected from moisture and light, and record receipt and batch details. The Learning Hub explains general storage principles; it does not replace batch-specific documentation. No preparation protocol or application quantity is supplied here.
Frequently asked questions
What does LY3437943 mean?
It is the development code associated with Retatrutide in the research literature.
What does “triple-receptor” mean here?
It refers to research involving GLP-1, GIP and glucagon receptors. It does not describe a guaranteed experimental outcome.
Can I use another size’s COA to verify my vial?
Not automatically. Verify the batch relationship first. The same compound name alone does not establish that the supplied material was the tested sample.
Where do I find current price and delivery details?
Use the product selector and checkout. The UK buying guide provides supporting purchasing and documentation context.
Research use notice
For laboratory research use only, Not for human or veterinary use. Supplied as a research chemical, not as a medicine, food or supplement. Information is for research documentation and does not provide application instructions.
Research you can verify.
Related reading
References
- Li W, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024. PubMed 39019866
- Neumann J, et al. Contractile effects of retatrutide in isolated mouse atrial preparations. Naunyn Schmiedebergs Arch Pharmacol. 2025. PubMed 40464942
- Tong LH, et al. Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application. J Chromatogr A. 2026. PubMed 42603384
Reviews
There are no reviews yet.